C
Claire N. Harrison
Researcher at Guy's and St Thomas' NHS Foundation Trust
Publications - 511
Citations - 24605
Claire N. Harrison is an academic researcher from Guy's and St Thomas' NHS Foundation Trust. The author has contributed to research in topics: Ruxolitinib & Myelofibrosis. The author has an hindex of 66, co-authored 424 publications receiving 19843 citations. Previous affiliations of Claire N. Harrison include St Thomas' Hospital & National Health Service.
Papers
More filters
Journal ArticleDOI
Personalized Prognostic Predictions for Patients with Myeloproliferative Neoplasms through Integration of Comprehensive Genomic and Clinical Information
Jacob Grinfeld,Jyoti Nangalia,E. Joanna Baxter,Anna L. Godfrey,Paola Guglielmelli,Rob Cantrill,David C. Wedge,Nicos Angelopoulos,Gunes Gundem,Charles E. Massie,Elli Papaemmanuil,Cathy MacLean,Julia Cook,Francesca L. Nice,Christen Lykkegaard Andersen,Christen Lykkegaard Andersen,Hans Carl Hasselbalch,Mary Frances McMullin,Alessandro M. Vannucchi,Claire N. Harrison,Moritz Gerstung,Peter J. Campbell,Anthony R. Green +22 more
TL;DR: This study sequenced the full coding regions of 68 genes and genome-wide single nucleotide polymorphisms and developed a unifying predictive model for all MPN patients, which generated accurate predictions on the training cohort, and performed well on internal cross-validation and on application to an external validation cohort.
editorialDOI
Treating Anemic Patients With Myelofibrosis in the New Janus Kinase Inhibitor Era: Current Evidence and Real-world Implications
Aaron T. Gerds,Prithviraj Bose,Gabriela S. Hobbs,Andrew T. Kuykendall,Lynn M. Neilson,Jinlin Song,Barbara Klencke,Claire N. Harrison +7 more
TL;DR: This study investigated 268 patients who discontinued ruxolitinib between June 2011 to October 2018 from a multicenter (consisting of 20 European hematology centers) observational retrospective study, and investigated reasons for discontinuation and impact on outcomes.
Journal ArticleDOI
Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies
Ruben A. Mesa,Moshe Talpaz,Jean-Jacques Kiladjian,Claire N. Harrison,Srdan Verstovsek,Sarah A. Buckley,Karisse Roman-Torres,John Mascarenhas +7 more
TL;DR: The safety profile in patients with severe thrombocytopenia was generally manageable and consistent with the overall study populations from the two phase 3 trials, and the intention-to-treat efficacy population was defined as all patients who received study drug.
Journal ArticleDOI
A physician survey on the application of the British Society for Haematology guidelines for the diagnosis and management of myelofibrosis in the UK.
TL;DR: This paper presents a meta-analyses of the prophylactic and experimental studies conducted at the University of Turin at Orbassano in 2016 showing clear trends in prognosis for certain types of childhood cancers and their prognosis in adults and children.
Journal ArticleDOI
How I manage myeloproliferative neoplasm‐unclassifiable: Practical approaches for 2022 and beyond
TL;DR: A contemporary overview of MPN‐U is provided in addition to four illustrative cases providing the collective suggested approaches to clinical challenges.